Literature DB >> 33015867

A pilot design for observational studies: Using abundant data thoughtfully.

Rachael C Aikens1,2, Dylan Greaves2, Michael Baiocchi1,2,3.   

Abstract

Observational studies often benefit from an abundance of observational units. This can lead to studies that-while challenged by issues of internal validity-have inferences derived from sample sizes substantially larger than randomized controlled trials. But is the information provided by an observational unit best used in the analysis phase? We propose the use of a "pilot design," in which observations are expended in the design phase of the study, and the posttreatment information from these observations is used to improve study design. In modern observational studies, which are data rich but control poor, pilot designs can be used to gain information about the structure of posttreatment variation. This information can then be used to improve instrumental variable designs, propensity score matching, doubly robust estimation, and other observational study designs. We illustrate one version of a pilot design, which aims to reduce within-set heterogeneity and improve performance in sensitivity analyses. This version of a pilot design expends observational units during the design phase to fit a prognostic model, avoiding concerns of overfitting. In addition, it enables the construction of "assignment-control plots," which visualize the relationship between propensity and prognostic scores. We first show some examples of these plots, then we demonstrate in a simulation setting how this alternative use of the observations can lead to gains in terms of both treatment effect estimation and sensitivity analyses of unobserved confounding.
© 2020 John Wiley & Sons Ltd.

Keywords:  assignment-control plots; causal inference; matching; observational studies; prognostic score; propensity score

Mesh:

Year:  2020        PMID: 33015867     DOI: 10.1002/sim.8754

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  2 in total

1.  Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors.

Authors:  Samuel A Funt; Deaglan J McHugh; Stephanie Tsai; Andrea Knezevic; Devon O'Donnell; Sujata Patil; Deborah Silber; Maria Bromberg; Maryann Carousso; Victor E Reuter; Brett S Carver; Joel Sheinfeld; Robert J Motzer; Dean F Bajorin; George J Bosl; Darren R Feldman
Journal:  Oncologist       Date:  2021-03-12

2.  Practical recommendations on double score matching for estimating causal effects.

Authors:  Yunshu Zhang; Shu Yang; Wenyu Ye; Douglas E Faries; Ilya Lipkovich; Zbigniew Kadziola
Journal:  Stat Med       Date:  2021-12-26       Impact factor: 2.373

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.